

This listing of claims will replace all prior versions, and listings, of claims in the application:


LISTING OF CLAIMS:

RECEIVED

FEB 24 0 2004

1.-11. (Canceled)

12. (Previously Presented) A compound of formula II




II

wherein radical R is:


$-(CH_2)_n-CH_2-R^1$ ,  $-(CH_2)_n-CH_2-OR^1$ ,  $-(CH_2)_n-CH_2-OCOR^1$ ,  $-(CH_2)_n-CH_2-SR^1$ ,  $-(CH_2)_n-CH_2-NR^1R^2$ ,  $-(CH_2)_n-CHO$ ,  $-(CH_2)_n-CN$ , in which n can assume the values of 0-5, and radicals  $R^1$  and  $R^2$ , independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.

13. (Currently Amended) ~~Process~~ A process for the production of  $5\beta$ -substituted androst-9(11)-enes of general formula II according to claim 12 by reaction of a compound of general formula I:



I


in which X = a halogen radical or a radiohalogen radical to form 17 $\beta$ -silyl ether of formula Ia



O-silyl group

Ia

in which X = halogen, selected from Br or I and further reaction with mercaptoacetic acid methyl ester for the formation of 17 $\beta$ -silylated-3-oxo-2'H,5'H-thieno[3',4':5,10]-5 $\beta$ -estr-9(11)-ene-2'-carboxylic acid methyl ester, which then is reacted according to processes that are known in the art analogously to Diagram 2 to form the a target compounds compound of Formula II:



II

wherein radical R is:

-(CH<sub>2</sub>)<sub>n</sub>-CH<sub>2</sub>-R<sup>1</sup>, -(CH<sub>2</sub>)<sub>n</sub>-CH<sub>2</sub>-OR<sup>1</sup>, -(CH<sub>2</sub>)<sub>n</sub>-CH<sub>2</sub>-OCOR<sup>1</sup>, -(CH<sub>2</sub>)<sub>n</sub>-CH<sub>2</sub>-SR<sup>1</sup>, -(CH<sub>2</sub>)<sub>n</sub>-CH<sub>2</sub>-NR<sup>1</sup>R<sup>2</sup>, -(CH<sub>2</sub>)<sub>n</sub>-CHO, -(CH<sub>2</sub>)<sub>n</sub>-CN, in which n can assume the values of 0-5, and radicals R<sup>1</sup> and R<sup>2</sup>, independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.

14. ~~(Currently Amended) Use of the compounds of general formula II according to claim 12 for treatment of~~ A method of treating an androgen-dependent diseases disease, comprising administering an effective amount of a compound according to claim 12 to a patient in need thereof.

15.-23. (Canceled)

24. (Previously Presented) A composition comprising a compound according to claim 12 and a pharmaceutically acceptable carrier.

25. **(Previously Presented)** A method of treating an androgen-dependent disease comprising administering an effective amount of a compound according to claim 12.

26. **(Previously Presented)** A compound according to claim 12, wherein R is an ethyl group.

27. **(New)** A compound according to claim 12, wherein R is 2-(2-pyrimidylsulfanyl)-ethyl, 2-(heptylsulfanyl)-ethyl, 2-[(1-methyl-1H-imidazole-2-yl)sulfanyl]ethyl, 2-(benzothiazole-2-yl)-sulfanyl, or [2-(thiene-2-yl)-sulfanyl]ethyl.